Success and failure of vaccines against renin–angiotensin system components

  title={Success and failure of vaccines against renin–angiotensin system components},
  author={Morris J. Brown},
  journal={Nature Reviews Cardiology},
  • Morris J. Brown
  • Published 1 October 2009
  • Biology, Medicine
  • Nature Reviews Cardiology
Therapeutic vaccination pre-dated modern drugs as a possible strategy for treating hypertension. This approach is now being rediscovered, through use of modified angiotensins as immunogens together with carriers and adjuvants. Effective blockade of the renin–angiotensin system (RAS) with treatment twice a year might suit patients who dislike taking drugs on a daily basis and would also be an attractive option for those who have blood pressures in the prehypertensive range, if it can prevent… 

Vaccines against components of the renin–angiotensin system

The different vaccination attempts with proteins and peptides against the different molecules of the renin–angiotensin system in the last two decades are reviewed, safety issues, and other novel prospects biomarkers in hypertension are summarized, and the potential of this immunomodulatory approach in clinical practice is summarized.

Effectiveness and Safety of a Therapeutic Vaccine Against Angiotensin II Receptor Type 1 in Hypertensive Animals

The ATRQ&bgr;-001 vaccine may provide a novel and promising method for the treatment of primary hypertension through diminishing the pressure response and inhibiting signal transduction initiated by Ang II.

Therapeutic Vaccines against Human and Rat Renin in Spontaneously Hypertensive Rats

The antigenic peptide hR32 vaccine mimicking the 32Asp catalytic site of human renin may constitute a novel tool for the development of a renin vaccine.

Emerging drugs which target the renin–angiotensin–aldosterone system

The search for drugs activating these tissue-protective arms of RAAS is the most innovative field in RAAS pharmacology, as newly discovered targets have functions beyond the cardiovascular system opening up novel therapeutic areas for drugs interfering with RAAS components.

Clinical study on angiotensin II vaccination—the first big step

  • M. Mogi
  • Medicine
    Hypertension Research
  • 2021
The present study was a phase I/IIa study of the angiotensin II vaccine AGMG0201 in patients with mild-to-moderate essential hypertension, and the vaccine was well tolerated at both low and high doses.

New Molecules for Treating Resistant Hypertension: a Clinical Perspective

Clinical trials of new molecules targeting both well-established and more recently elucidated pathophysiologic mechanisms of hypertension offer a multitude of potential treatment avenues that warrant further evaluation in the context of RH.

An Interesting Vaccine

The crucial role of renin angiotensin aldosterone system (RAAS) in the pathogenesis of hypertension is now well recognized and the use of drugs to block this system has become an important modality in the management of hypertension.

New approaches in the treatment of hypertension.

New drugs and interventional treatments that are undergoing preclinical or clinical testing for hypertension treatment are discussed, but none of these novel drug or device treatments has been shown to prevent cardiovascular disease outcomes or death in hypertensive patients.

Gene therapy for hypertension

Increased gene transfection efficacy necessary for a systemic treatment, personalized identification of the implied aetiology from the multifactorial background and evidence from larger mammals are required for gene therapy to compete with the broad spectrum of current therapeutic options in hypertension.

Renin inhibition by soyasaponin I: a potent native anti-hypertensive compound

The results of this survey might be helpful to design partial non – competitive renin inhibitors with pharmaceutical capability and have partial non-competitive effect.



A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

AngQb reduces blood pressure in SHR to levels obtained with an ACE inhibitor, and is immunogenic and well tolerated in humans, Therefore, vaccination against angiotensin II has the potential to become a useful antihypertensive treatment providing long-lasting effects and improving patient compliance.

Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

KH was shown to be a suitable alternative to TT as a carrier protein for AI, thus supporting continued evaluation of the AI-KLH conjugate vaccine for treatment of hypertension in man.

Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.

Biochemical measurements show evidence of blockade of the renin system, but higher titres will be required to achieve a decrease in blood pressure, as shown in patients with essential hypertension.

Renin-angiotensin vaccine: old story, new project 'efficacy versus safety'.

  • J. Michel
  • Medicine, Biology
    Clinical science
  • 2004
Preliminary results of Ang I (angiotensin I) immunization in humans demonstrate the presence of antibodies in human plasma and report that the procedure is well tolerated, but the blood pressure does not fall.

Immunologic approaches to blockade of the renin-angiotensin system: a review.

Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats

Findings indicate that active immunization against AI may be a useful approach for treating cardiovascular disorders involving the renin‐angiotensin system.

Active and Passive Immunization Against Angiotensin II in the Rat and Rabbit: EVIDENCE FOR A NORMAL REGULATION OF THE RENIN-ANGIOTENSIN SYSTEM

It is concluded that the renin-angiotensin system in antibody-injected rats was regulated at a normal level, and feedback mechanisms which control renin secretion, such as free plasma angiotens in II concentrations, are in the normal range.

Better blood pressure control: how to combine drugs

This article shows how the consistency of both theory and a broad range of evidence permits a didactic approach to combination therapy and advises against combining ‘B’ and ‘D’ in older patients, and to recommend ‘A’ + ‘C” + “D” as standard triple therapy for resistant hypertension.

Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.

It is demonstrated that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects.